PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'COVID-19 Research Center, The First School of Clinical Medicine, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Southern Medical University, Nanjing, China.\', \'Medical and Technical Support Department, Pingdingshan Medical District, The 989th Hospital Pingingshan, Pingdingshan, China.\', \'Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan, China.\', \'General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.\', \'Department of Laboratory Medicine, Nanjing Red Cross Blood Center, Nanjing, China.\', \'Institute of Blood Transfusion, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.\', \'Department of Blood Transfusion, Jingling Hospital, Nanjing University School of Medicine, Nanjing, China.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.3389/fimmu.2021.598799
?:doi
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 33746945
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
is ?:relation_isRelatedTo_publication of
?:title
  • Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33746945>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33746945>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all